AI biotech Enveda raises $311M, valuation doubles to $2B
emmanuelvivier · x · 2026-09-25
AI drug-discovery biotech Enveda raised $311M, doubling its valuation to $2B, with three AI-designed treatments now in clinical trials. Also: Gemini's new "Call for Me" feature can call automated phone menus on your behalf with live transcription, coming to Pixel 11.
Related event: AI drug discovery firm Enveda raises $311M at $2B valuation(2 posts)→
More from Venture
- Investor argues analogy-based AI capex bubble takes underestimate LLMs' self-induced demand — menhguin · 2026-11-11
- Nvidia's supply commitments jump from $119B to $279B in one quarter, locking up 2027-28 memory — tengyanAI · 2026-11-11
- Crypto x AI at ATH: onchain inference nears 2T tokens/day — 0xJeff · 2026-11-11
- NVIDIA expands Meta Muse partnership, invests $3B in Meta stock — armand_ruiz · 2026-11-11
- Gary Marcus flags: OpenAI's biggest backer SoftBank faces 33% bankruptcy odds in 5 years — GaryMarcus · 2026-11-11
- Ramp hid an AI-only offer on its site; AI mentioned it to buyers 370 times in 32 days — VeryWellVersed · 2026-11-11